Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease.

ABSTRACT:

Background

Impaired brain bioenergetics is a pathological hallmark of Alzheimer's disease (AD) and is a compelling target for AD treatment. Patients with AD exhibit dysfunction in the brain creatine (Cr) system, which is integral in maintaining bioenergetic flux. Recent studies in AD mouse models suggest Cr supplementation improves brain mitochondrial function and may be protective of AD peptide pathology and cognition.

Aims

The Creatine to Augment Bioenergetics in Alzheimer's disease (CABA) study is designed to primarily assess the feasibility of supplementation with 20 g/day of creatine monohydrate (CrM) in patients with cognitive impairment due to AD. Secondary aims are designed to generate preliminary data investigating changes in brain Cr levels, cognition, peripheral a

SUBMITTER: Taylor MK 

PROVIDER: S-EPMC10898014 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature